Claim · 2024-10-09 · announcement · Stated in source · Supported

insitro announced on 9 October 2024 three strategic agreements with Eli Lilly and Company on potential new medicines for metabolic diseases.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

insitro → announced a partnership with → Eli Lilly and Company

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

insitroannounced a partnership with ↓Eli Lilly and Company

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Date: 2024-10-09 · announcement Records dated 2024 →
Activity stage: announced

Scope and limitsAn announced arrangement; the release discloses no amounts in the passage quoted, and the record does not establish that any programme reached the clinic.

The evidence 01

primary sourceSupports the claim

insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases

insitro · 2024-10-09

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“today announced the execution of three strategic agreements with Eli Lilly and Company (Lilly) focused on advancing potential new medicines for metabolic diseases”

Location in source first paragraph

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: insitro
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 3f7bccc4cabec363eae2733d572858418f2c8a53606d121ca0a33e509e458645). insitro news page, dated 10/09/2024 on the page, as served on 2026-10-30. Its wording can change; earlier wording is not authenticated.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: insitro, “insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases”, 2024-10-09.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (23 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A22) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An organisation announced a collaboration or partnership with a named counterparty, as the announcement states it (stage announced). It is not evidence that the work was performed, that a payment was made or that the arrangement continues; an “up to” amount stays in the statement.

Date. Date of insitro's release.

Record ID aib-co-insitro-lilly-2024